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1. Abstract
1.1. Aims
Stereotactic body radiation therapy (SBRT) is one of the standard radical treatments in stage I non-
small cell lung cancer (NSCLC) and an option for lung metastases. The pulmonary parenchymal CT 
alterations at 3, 6 and 12 months are the object of a prospective analysis in patients submitted to SBRT, 
to define factors affecting the different radiological alterations. The isodoses better conformed to the 
damaged pulmonary volume will be identified; the time course of CT alteration is also addressed.
1.2. Materials and Methods
CT images of patients treated with SBRT for primitive or lung metastases were reviewed. 
Planning target volume (PTV), comorbidity, type of tumor, were related to patterns of lung toxicity 
(dense, ground glass or both).
1.3. Results
From 2012 to 2015, 56 patients were treated with SBRT (55 Gy in 5 fractions schedule). In terms of 
dimension of PTV, the pattern of toxicity changes at 3 (p = 0.009), 6 (p = 0.001) and 12 (p = 0.002) 
months, showing that small nodules developed ground glass patterns and bigger nodules a dense one. 
Pattern of toxicity changed at 3 (p = 0.003) and 6 months (p = 0.026) in relation with comorbidities, 
but not at 12 months.
1.4. Conclusions
The pattern of lung toxicity changed during the first year after SBRT. Old patients with several 
comorbidities repair differently lung damage with consequently particular type of toxicity pattern. 
A deeper understanding of the isodose that better conforms to damaged volume could contribute to 
distinguish radiation induced lung injury from disease progression.
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3. Introduction
Stereotactic body radiation therapy (SBRT) has been adopted since 
the mid-1990s for treating lung nodules, including early stage 
non-small cell lung cancer (NSCLC) and lung oligometastases [1], 
yielding excellent local control rates [2]. 
Fifteen to twenty percent of patients diagnosed with NSCLC 
have stage I disease [3]. Treatment of choice in early stage 
NSCLC is surgery. Dang Han-Yu et al. [4] reported the results 
of a meta-analysis comparing surgery versus SBRT in this subset 
of patients. The same authors reported also two subgroup meta-
analyses comparing SBRT versus lobectomy and versus sub-lobar 
resection. These studies demonstrated a significant difference in 
terms of overall survival (OS) favouring surgery and in particular 
lobectomy. The authors concluded that SBRT offers good short-
term control of early-stage NSCLC but that lobectomy is still the 
standard treatment, due to better long-term prognosis. 
Two randomized phase III trials comparing lobectomy and SBRT 
(STARS and ROSEL, ClinicalTrials.gov, STARS: NCT00840749, 
ROSEL: NCT00687986)) [5] in medically operable stage I NSCLC 
have been performed but none of them reached the number of 
patients expected to be enrolled. A pooled analysis of these two 
trials, however, showed a benefit in OS for SBRT.
However, several authors pointed out that it is difficult to compare 
SBRT data to surgical series. Ricardi et al. [6] after a median follow-
up of 20.4 months after SBRT on lung metastases found out that 2 
and 3 Years local control rates were 89% and 83.5% respectively, 
overall survival 66.5% and 52.5%, cancer-specific survival 75.4% 
and 67%, progression-free survival 32.4% and 22.3%. They 
concluded that lung SBRT, also without histological confirmation, 
appear promising also considering issues as patients compliance to 
treatment, toxicity profile, and cost-effectiveness parameters.
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Table 1: RTOG Common Toxicity Criteria for lung toxicity
Grade  
0 None
1 Asymptomatic or mild Symptoms (dry cough) Slight radiographic appearances
2
Moderate symptomatic fibrosis or pneumonitis (severe 
cough) 
Low grade fever 
Patchy radiographic appearances
3 Severe symptomatic fibrosis or pneumonitis Dense radiographic changes
4 Severe respiratory insufficiency/Continuous O2/ Assisted ventilation
5 Death related to radiation effects
Grade




1 Shortness of breath with moderate exertion
2 Shortness of breath with minimal exertion; Limiting instrumental ADL
3 Shortness of breath at rest; Limiting self care ADL
4 Life-threatening consequences; urgent intervention indicated
5 Death
Table 2: CTCAE Common Terminology Criteria for Adverse Events for dyspnea.
Grade
Acute Lung Tox 
(RTOG)
Acute Esophageal Tox 
(RTOG) Late Lung Tox (RTOG) Late chest wall Tox (RTOG)
N patients Percentage N patients Percentage N patients Percentage N patients Percentage
0 39 70 51 91 30 54 47 84
1 12 21 3 5 18 32 0 0
2 3 5 2 4 7 13 4 7
3 2 4 0 0 0 0 1 2
4 0 0 0 0 1 2 4 7
Table 3: Description of patients toxicities referring to RTOG scales.
 3 months 6 months 12 months
PATTERN Primitive Metastasis Primitive Metastasis Primitive Metastasis
G r o u n d 
glass
59,1% 40,9% 57,8% 42,2% 50,0% 50,0%
Dense 63,6% 36,4% 40,0% 60,0% 58,3% 41,7%
G r o u n d 
glass + 
dense
55,6% 44,4% 60,0% 40,0% 63,6% 36,4%
Table 4: Lung alteration patterns variations over time (3, 6 and 12 months after 
SBRT) according to the type of tumor (primitive or metastasis).
In a very recent retrospective multicenter analysis (2019) Scotti et 
al. [7] at univariate analysis no significant difference was found in 
local control between patients who underwent SBRT or lobectomy, 
with a trend in favor of surgery. Overall survival was significantly 
better in patients who underwent lobectomy; however, no 
difference in overall survival was observed between operable 
patients undergoing SBRT and patients that underwent lobectomy. 
Progression free survival was comparable between patients who 
underwent lobectomy and SBRT.
Even considering surgery as the treatment of choice for early stage 
NSCLC, about thirty percent of patients are not operated, due to 
older age, medical comorbidities or because of their preferences.
In this setting, a better level of evidence on SBRT is available: a 
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 3 months p=0.0009 3 months p=0.0001 3 months p=0.0002








Sum PTV ≤ 28.1 cc PTV > 28.1 cc Sum
Ground glass 32.2% 9.4% 41,6% 31.5% 3.7% 35,2% 42.6% 8.5% 51,1%
Dense 13.2% 28.3% 41,5% 11.1% 16.7% 27,8% 10.6% 14.9% 25,5%
Ground glass 
+ dense
7.5% 9.4% 16,9% 13% 24% 37% 6.4% 17.0% 23,4%
Sum 52,9% 47,1% 100,0% 55,6% 44,4% 100% 59,6% 40,4% 100%
Table 5: Lung alteration patterns variations over time (3, 6 and 12 months after SBRT) according 
to PTV volume.
 3 months p=0.0009 3 months p=0.0001 3 months p=0.0002
PATTERN CCI ≤ 4 CCI ≥ 5 Sum CCI ≤ 4 CCI ≥ 5 Sum CCI ≤ 4 CCI ≥ 5 Sum
Ground glass 28.3% 13.2% 41,6% 22.2% 13.0% 35,2% 25.5% 25.5% 51%
Dense 9.4% 32.1% 41,5% 3.7% 24.0% 27,7% 6.4% 19.1% 25,5%
Ground glass + 
dense
9.4% 7.5% 16,9% 20.4% 16.7% 37,1% 15.0% 8.5% 23,5%
Sum 47,% 52,8% 100,0% 46,3% 53,7% 100% 46,9% 53,1% 100%
Table 6: Lung alteration patterns variations over time (3, 6 and 12 months after 
SBRT) according to CCI.
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U n d e r 
median 35 43 47 52 40 49 50 35 46
O v e r 
median 49 49 51 76 37 46 73 38 48
Charlson Com 
orbidity Index
≤ 4 42 44 49 69 37 52 71 34 51
≥ 5 41 46 49 57 41 44 49 38 43
Lung Toxicity 
Pattern
G r o u n d 
Glass 50 42 46 56 39 48 50 37 46
Dense 27 50 49 50 37 43 63 35 50
GG + 
Dense 57 43 56 78 40 51 76 35 43
Table 7: Quantitative analysis of how the lung toxicity volumes and is dose curves 
change according to PTV, CCI and lung toxicity pattern.
Phase 1 study conducted at Indiana University showed that 
patients with stage I disease treated with escalating SBRT doses had 
crude rates of local failure of 21%. A dose response was recognized 
with a cut-off value of 16 Gy for single fractions [8, 9]. A Phase 
2 multicenter trial (RTOG 0236) [10] evaluated SBRT’s toxicity 
and efficacy in a high risk population of patients with early stage 
medically inoperable lung cancer, concluding that the survival 
rate at 3 years was of 55.8% with high rates of local tumor control 
(97.6%) and moderate treatment-related morbidity. 
The SPACE study [11] randomized patients with stage I medically 
inoperable NSCLC to receive SBRT (66 Gy in 3 fractions) or 
3DCRT (70 Gy in 35 fractions). No differences were found in terms 
of progression free survival, overall survival and local control; 
toxicity was generally mild in both treatment arms.
Based on these studies, SBRT is now the standard of care for 
inoperable early stage NSCLC. Nonetheless, even if local control 
rates are excellent, distant failure is common, occurring in 20-30% 
of patients in 3-5 years [12]. 
SBRT for lung oligometastases represents a different scenario; 
many data support this therapeutic approach mainly to postpone 
systemic treatment [13]. 
During follow up, usually 3-4 months after SBRT, a shadow 
corresponding to the irradiated area appears, characterized by 
shrinkage of the pulmonary parenchyma. Sometimes on this area 
symptomatically radiation pneumonitis develops. The shadow of 
the treated nodule blends itself with the shadow of the radiation 
pneumonitis area, making it difficult to distinguish one from the 
other. If the dimensions of the shadow remain stable during the 
follow up, the tumor is generally considered controlled, because 
likely no vital tumor cells are present. Conversely, if the shadow 
starts to grow and enlarges vital residual cells and uncontrolled 
tumor are supposed to be present. Sometimes, in relation to these 
radiological signs, many years are necessary to be sure that local 
control has been achieved. Several authors stated that the presence 
of a residual mass is not necessarily indicative of a possible future 
recurrence and, in some cases, the tumor seems to be controlled 
even if a mass shadow persists [2, 14].
To date, to differentiate pulmonary parenchymal CT alterations 
after stereotactic body radiation therapy (SBRT) from local relapse 
remains difficult. 
The purpose of this study is to evaluate in retrospect clinical 
toxicities and radiological lung alteration in a cohort of patients 
treated with SBRT for lung nodules. Moreover, this study aims to 
define which factors could affect CT volumes and pattern of lung 
toxicity and to assess the isodose curves that better conform to the 
damaged pulmonary volume. CT alterations time course has been 
also addressed.
4. Patients and Methods
4.1. Patients selection 
From 2012 to 2015 91 patients were treated with lung SBRT at the 
Brescia University Radiation Oncology Department: 46 lesions 
were primary lung cancers and 45 were secondary nodules from 
lung or other primary tumors.
All the patients were treated with 55 Gy in 5 fractions; they had the 
entire radiological follow up at the Brescia University Radiology 
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Figure 1: percentage of different patterns at 3, 6 and 12 months of follow up.
Figure 2: This picture reports lung damage in a patient with a nodule in left lung. 
In particular it is depicted how lung damage progresses during time at 3, 6 and 12 
months after SBRT.
Department. The present study is therefore limited to 56 patients 
and 60 lesions. 
The patients comorbidities were defined using the Charlson 
Comorbidity Index, CCI, a system integrating information about 
clinical conditions, comorbidity and patients age. Fit patients had 
CCI ≤ 4; patients were considered un-fit if CCI was ≥ 5. 
 4.2. SBRT methods
Patients were positioned on a wing board and respiratory motion 
was reduced by abdominal compression. A 4D CT scan (Philips 
Brilliance CT, Philips, Cleveland, USA, ®) was obtained, using five 
image reconstruction phases (from 0 to 80%), with 0% representing 
the end of inspiration, 40% representing half of a respiratory cycle 
and 80% representing the completed cycle. 
Contouring was conducted with Nucletron Oncentra MasterPlan 
® (Columbia, USA) and planning with Philips Pinnacle ® 
(Massachusetts, USA). 
The Gross Tumor Volume (GTV) was identified on axial CT using 
pulmonary windowing (considering the window width at +1600 
Hounsfield Units and the window level at -600 Hounsfield Units). 
After having contoured the five different GTVs, corresponding to 
the five image reconstruction phases, the Internal Target Volume 
(ITV) was defined, including all the GTV contours. The Planning 
Target Volume (PTV) was created by expanding the ITV 0.9 cm in 
all direction.
All patients were treated using Volumetric Modulated Arc Therapy 
(VMAT), with daily image guidance with 3D Cone-Beam kV CT 
(IGRT). SBRT was delivered using two Elekta Synergy ® linear 
accelerators. The treatment was given in 5 consecutive 11 Gy daily 
fractions. 
4.3. Follow up procedures: radiological and clinical evaluation 
After SBRT completion, radiological and clinical follow up begun 
prospectively for all treated patients, at defined time points (3, 6 
and 12 months), according to institutional policy.
Radiological follow up was carried out with multi detector row 
computed tomography (MDCT) scanner at 3, 6 and 12 months. All 
the MDCT exams were performed at the Radiology Department 
of our University using a 128-detector CT scanner (Soma tom 
Definition Flash; Siemens healthcare, Forchheim, Germany) with 
the following parameters: collimation, 128x0.6 mm; beam pitch, 
1.2; rotation time, 0.5 s; tube voltage, 120 kVp; and tube current, 110 
mAs. The acquisition, extending from the lung apex to lung base, 
was performed in inspiratory apnea. The volume was reconstructed 
as 1 mm thick sections, applying a sharp reconstruction algorithm 
and lung window setting. Only unenhanced MDCT images were 
used for image evaluation.
Clinical follow up was performed in order to evaluate local control 
and regional or distant progression. It was used a cut off of 3 months 
to distinguish between acute and late toxicity. Reported toxicities 
were assessed using different evaluation scales. In particular, acute 
lung and esophageal toxicities were determined with reference to 
RTOG Common Toxicity Criteria, as well as late lung and chest 
wall toxicity. Late dyspnea was also assessed according to CTCAE 
(Common Terminology Criteria for Adverse Events) v. 5.0 (2017). 
RTOG and CTCAE scales are reported in Table 1 and 2.
4.4. Evaluation of the characteristics of the lung toxicity 
during follow up
Three different patterns of lung toxicity in follow up CT scans were 
defined in order to classify lung toxicity patterns [12-16]:
•    Dense pattern: represented by a region with “solid” high density, 
where blood vessels cannot be recognized;
•    Ground Glass (GG) pattern: with higher density than normal 
lung parenchyma, but with the possibility of seeing blood vessels;
•    Mixed pattern: characterized by both dense and GG patterns. 
In this study planning CT were co-registered with 3, 6 and 12 
months follow-up CT. These images were obtained in different 
respiratory phases and with different setup. The comparison was 
possible using the Varian Medical Systems software Velocity ® 
(Velocity Medical Solutions, Atlanta, Georgia, USA). This software 
works through a modified B-spline calculation algorithm, that 
computes the 3D displacement necessary for voxels to reach 
optimal fits and contours attached to specific voxels are deformed 
and warped with the same 3D displacement. 
Both the CT scan images at 3, 6 and 12 months after SBRT and the 
SBRT planning images were sent to to the Velocity ® software.
The first step was a rigid registration, providing a good 
correspondence between the bone structures of the two sets of 
images; on the contrary, the results of the matching of the treated 
lesion with the lung toxicity area and the thoracic wall were 
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unsatisfactory.  
Thus, a second step was a deformable registration the lung region 
of interest. This allowed us to obtain a better coregistration of the 
treated nodule with the lung toxicity area and the thoracic wall 
(3-5 mm precision). After deformation, matching was qualitatively 
evaluated by comparing locations of major structures (for example 
great vessels, chest wall, major airways). 
The third step was the contouring of the lung visible alterations 
areas in the follow up CT at 3, 6 and 12 months. 
Finally, these contoured areas were compared with the planning 
volumes and the isodose curves. 
In a preliminary phase radiation oncologists were trained by a 
radiologist, in order to better identify the three different alterations 
pattern. At the beginning CT scans were contoured by two double-
blinded radiation oncologists. The contours obtained in the first 10 
patients were compared and no significant differences were found 
between the two operators. The study was therefore continued by a 
single radiation oncologist.
To evaluate the relations between PTV volume and lung alterations 
a median PTV volume has been calculated, in order to understand 
if lung alterations change in relation to PTV volumes. 
 5. Statistical Analysis
The data are presented as numbers (%) or the mean ± standard 
deviation for normally distributed data or as the median and 
interquartile range (IQR) for not normally distributed data.
The relationship between the different clinical and treatment 
variables (type of nodule, primary vs metastatic; age, presence of 
COPD, Karnofsky index, CCI, Planning Target Volume – PTV) 
with the type of lung abnormalities (ground glass, dense, mixed) 
was analyzed.
To compare different variables χ-square test, Student t test and 
Anova test were used. Student t test was used to investigate two 
groups of patients and Anova test to compare more than two 
groups of patients. 
The SPSS ® software (IBM, Chicago, Illinois, USA) was used for 
statistical analysis, using two-sided statistical testing with p = 0.05 
indicating statistical significance.
6. Results 
From 2012 to 2015, 56 patients and a total number of 60 nodules 
were treated with SBRT for primary stage I NSCLC or pulmonary 
metastasis with a 55 Gy in 5 fractions schedule. 
Forty-five percent of patients had a Charlson Comorbidity Index 
lower than 5 (CCI ≤ 4) and 55% had CCI ≥ 5. 
Among all patients, 39 (70%) were asymptomatic, while 17 
presented mild or moderate lung toxicity and none had severe lung 
toxicity. Only 5 patients (9%) reported acute esophageal toxicity. 
Late lung RTOG toxicity was assessed in 26 of patients (47%). Late 
chest wall toxicity was found in 9 patients (16%), manifesting with 
rib fracture. 
All these results are reported in Table 3.
Late dyspnea described using CTCAE scale was reported by 35 
patients out of 56 (63%). Sixteen patients (29%) reported grade 1 
dyspnea, 17 patients grade 2 dyspnea (30%), 1 patient (2%), grade 
3 and 1 patient grade 4 dyspnea. It is also interesting to notice 
that the majority of these patients (30 out of 35, 85.7%) already 
presented mild or moderate dyspnea before radiation treatment. In 
particular, the patients that reported grade 3 dyspnea already had 
previously grade 2 dyspnea and the patient that reported grade 4 
dyspnea already had grade 3 dyspnea. 
Loco-regional progression of disease 
Twelve patients out of 56 (21%) showed loco-regional relapse of 
disease. Of these patients, 7 presented nodal mediastinal relapse, 
while in 5 patients massive lung progression was described, with 
the appearance of several lung nodules. All of these five patients 
had an increase in the dimensions of the treated lung lesions and 
also in-field progression.
Fifty-eight percent of the cases had primitive lung cancer, 30% 
were treated for lung cancer metastases and 11.7% for metastases 
from other primitive tumors. 
Three months after SBRT 41.5% of patients had GG pattern, 41.5% 
dense toxicity and 17% mixed pattern. At 6 months, 35.2% of 
patients had GG changes, 27.8% had dense parenchymal alterations 
and 37% had mixed pattern. At 12 months, GG, dense and mixed 
patterns were respectively present in 51%, 25.5% and 23.5% of 
patients (Figure 1).
The different toxicity areas deriving from treating lung cancer, 
metastases from lung cancer or metastases from different tumors 
tended to increase in volume during time. 
Lung alteration patterns variations over time (3, 6 and 12 months 
after SBRT) according to the type of tumor (primitive or metastasis) 
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are reported in Table 4.
The median PTV volume was 28.1 cc (range 8.86 - 108.0 cc). Lung 
alterations resulted different in relation to PTV volumes.
A ground glass pattern of lung alteration was more represented for 
nodules with PTV < 28.1 cc. Three, 6 and 12 months after SBRT, GG 
pattern rate resulted significantly higher for small nodules 32.1% 
(p=0.009), 31.5% (p=0.001) and 42.6% (p=0.002), respectively 
(Table 5). 
The pattern of lung damage significantly changes at 3 and 6 
months but not at 12 months (p = 0.009 and 0.009, respectively) 
in relation with CCI. In particular, 28.3% of the fit patients (CCI 
≤ 4) developed a ground glass pattern at 3 months and 22.2% at 6 
months, while in older patients with several comorbidities (CCI ≥ 
5) dense toxicity was the more frequently observed pattern, 32.1% 
at 3 months and 24.1% at 6 months.
Lung changes variations over time (3, 6 and 12 months after SBRT) 
according to the score of Charlson Comorbidity Index are reported 
in Table 6.
7. Dosimetric Evaluation
The quantitative analysis of how lung toxicity volumes and isodose 
curves change according to PTV, CCI and lung toxicity pattern is 
reported in table 7.
Patients with larger PTV showed a non-significantly lung alteration 
volume, increasing with time after SBRT. In parallel, isodose curves 
values encircling the lung toxicity areas (included in the 35 - 50 
Gy isodose range), tended to decrease in dimension during the 
12 months of follow up, being substantially superimposable for 
patients with high and low CCI.
Patients with CCI ≤ 4 showed larger damaged volume than unfit 
patients (differences not statistically significant) that increased at 
the various time intervals after SBRT (42 cc, 69 cc and 71 cc at 3, 
6 and 12 months, respectively). The values (in Gy) of the isodoses 
better conforming to the damaged lung volume decreased during 
the follow up, ranging in the different subgroups analysed between 
42  and 50 Gy at 3 months, 37 Gy and 41 Gy at 6 months, 35 Gy and 
38 Gy at 12 months. 
Evaluating the conformal index (CI) at 3, 6 and 12 months, the 
isodose conformation around the damaged area is about 50%. 
8. Discussion 
The main aim of this study was to evaluate clinical toxicities and 
radiological lung alteration in a cohort of patients treated with 
SBRT for lung nodules. As already described in literature our series 
reported a low rate of toxicity. 
This series attempts to take advantage from more precise three-
dimensional evaluation of the shape of lung damaged regions and 
of dose envelopes. 
Therefore the data from this series add to the literature on the 
value of the isodose curve that more accurately conforms to the 
area involved by CT-defined lung toxicity. This dose–alteration 
correlation might have an important application during follow up 
after SBRT: in fact, it could help to distinguish recurrence from 
benign changes based on the knowledge of the relevant isodose 
curves and on the degree of normal density changes after SBRT. 
We observed that the isodose curves better fitting with the extent 
of CT-evident lung toxicity are in the 35-50 Gy range. Even if this 
range seems large, it corresponds to a 5-30 mm radius around the 
area of interest on the CT slice. 
The time course of RILD is known since more than 30 years 
[17]. However to help to semi-quantitatively distinguish between 
disease relapse/progression and RILD, a few authors tried to define 
the isodose curves that correspond to pulmonary alterations. Our 
results are generally in agreement with these studies, that outline 
modest increases in CT density above 20-30 Gy and profound 
changes at doses above 60 Gy. 
Palma et al. [18] in a 2011 study reported that density increases 
mostly at doses > 20 Gy, with a plateau above 30 Gy. They also 
reported in another study conducted in the same year [19] that 
the largest increases in lung density are noted in regions receiving 
more than 50 Gy. 
Aoki et al. [20] report that the minimal lung dose to the area with 
pulmonary injury ranges between 16 and 36 Gy, with a median of 
24 Gy.
Knoll et al. [1] noticed that the 20 Gy isodose curve approximates 
the pattern and shape of the observed radiation induced lung 
injury and is not predictive of recurrence.
In our series, patients with CCI < 4 showed smaller nodules and 
presented mainly a GG lung damage that tended to decrease 
during follow up. On the contrary, patients with CCI > 5 tended to 
have greater nodules and developed a dense lung damage that often 
increased in dimensions during follow up.  
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The fact that old patients tend to have greater nodules could 
have more than a clinical explanation. In fact old people with 
comorbidities could have a late diagnosis of lung nodules (primitive 
or metastasis), and therefore these lesions could be larger. In elderly 
with comorbidities diagnosed with a large lung nodule, surgery is 
not feasible. Therefore, the increase of lung toxicity area during 
follow up could be explained and related to the initial greater 
dimension of the lesion. 
In literature a few studies [21-24] reviewed the mechanisms of 
lung damage from a histologic point of view. The mechanisms of 
damage can be resumed as follow:
a month after SBRT, a damage to type I and type II pneumocytes 
can be observed. Subsequently there is a reduction of surfactant 
production and the alveoli tend to collapse. Moreover, it appears a 
vascular damage with an increase of vessel permeability leading to 
interstitial edema;
3-6 months after SBRT, there is an incessant inflammatory response, 
with proliferation of leucocytes, plasmacells, macrophages, 
fibroblasts that provide collagen fibers deposition. A thickening of 
alveolar septa Is also observed; 
6-9 months after SBRT, fibrosis starts to develop with capillary loss, 
further alveolar septa thickening and obliteration of alveolar space; 
1-2 years after SBRT, the full picture of pulmonary fibrosis is 
evident, as consequence of the lung damage repair process. This 
process is mediated by macrophages that stimulate a cytokine 
cascade (mainly represented by TNF-alpha, TGF-beta, IGF-1, 
PDGF), that consequently recruits fibroblasts, responsible of 
fibrotic damage. These cascades are stimulated by the activation of 
promoters like NFKB and AP1 (encoded by Jun and FOS genes), 
that enhance cytokines genes transcription. 
The consequent development of pulmonary fibrosis is limited to 
the treated area where radiation induced cytokine release takes 
place. 
8.1. This process is represented by the following CT scan 
density changes
One month after SBRT, is often impossible to see changes of lung 
tissue; 
Approximately 3-6 months after SBRT, the consolidation, in 
the high-dose region of pulmonary parenchyma, and ground 
glass alteration in the low dose region begin to be seen. This is 
considere d as acute radiation pneumonitis;  
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between 6 and 9 months after SBRT, consolidation develops into 
solid or dense consolidation, seen at CT imaging as a dense opacity; 
This process evolves, until at 1-2 years after SBRT, when the 
pulmonary opacities become stable. 
If there will not be cancer recurrence, these areas will tend not to 
change in their extension and morphology. 
This whole process is represented in Figure 2. 
Aging is associated with a chronic pro-inflammatory state [25-
27] characterized by elevated levels of circulating cytokines, such 
as IL-1, Il-6, TNF-alpha, leading to the definition of the so-called 
“inflamm-aging”, a subclinical inflammatory status characterized 
by a lifelong continuous stimulation of the immune system. 
So it can be hypothesized that in older patients with comorbidities 
who underwent radiotherapy, a lung damage repair mechanism is 
activated, causing a continuous inflammatory response after SBRT. 
This reaction is characterized by a perpetual pro-inflammatory 
state, leading to an enhancement of the inflammatory state, 
resulting in an increased production of cytokines (with a leading 
role played by TNF-alpha). Fibroblast activation and fibrosis 
development follow. Fibrotic areas are those characterized by a 
dense pattern in follow up CT scans. This could explain why older 
people with comorbidities tend to develop a dense toxicity pattern, 
that increases during the first year of follow up. 
However, these hystopatological and radiographic findings do not 
correlates with increased clinical toxicity. Thus, elderly patients 
remains ideal candidates for SBRT, especially those unfit for 
surgery.  
9. Conclusion
The “shape” of lung toxicity changes during the first year after SBRT, 
leading to lung fibrosis within 12 months. Old patients with several 
comorbidities have a different capability to repair lung damage and 
they consequently show higher incidence of this type of pattern. 
Young and fit patients tend to have smaller nodules and they show 
a GG damage that decreases during follow up. 
In addition to the knowledge of the “shape” of isodose curves, this 
could allow to better distinguish radiation induced lung injury 
from disease progression.
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